Insider Selling: Aardvark Therapeutics (NASDAQ:AARD) Insider Sells 14,754 Shares of Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 14,754 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $5.00, for a total value of $73,770.00. Following the completion of the transaction, the insider directly owned 97,475 shares of the company’s stock, valued at approximately $487,375. The trade was a 13.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Nelson Sun also recently made the following trade(s):

• On Friday, September 11th, Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00.

Aardvark Therapeutics Trading Up 2.4%

AARD stock traded up $0.12 during trading on Friday, hitting $5.13. 276,559 shares of the stock traded hands, compared to its average volume of 128,424. Aardvark Therapeutics, Inc. has a one year low of $3.35 and a one year high of $17.94. The stock has a market cap of $112.24 million, a price-to-earnings ratio of -1.60 and a beta of 3.74. The company has a 50 day simple moving average of $6.29 and a 200 day simple moving average of $5.53.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21. As a group, analysts predict that Aardvark Therapeutics, Inc. will post -3.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Morgan Stanley reissued an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. B. Riley Financial decreased their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $15.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at $42,000. Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics in the fourth quarter valued at about $56,000. New York State Common Retirement Fund bought a new position in Aardvark Therapeutics in the second quarter valued at about $99,000. MetLife Investment Management LLC acquired a new stake in Aardvark Therapeutics in the fourth quarter worth about $102,000. Finally, Bank of America Corp DE increased its position in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after purchasing an additional 3,369 shares during the period.

Aardvark Therapeutics News Roundup

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.